NightHawk Biosciences, Inc., formerly Heat Biologics, Inc., is a fully integrated biopharmaceutical company. The Company specializes in the end-to-end development and commercialization of therapies that arm the immune system against a range of diseases including cancer and infectious disease. It focuses on drug development through its integrated ecosystem of subsidiary companies, which includes Skunkworx Bio (Skunkworx), Heat Biologics (Heat), Pelican Therapeutics (Pelican), Scorpion Biological Services (Scorpion) and Elusys Therapeutics (Elusys). It offers three technology platform, namely gp96, which leverages the immune stimulatory properties of the heat shock protein gp96 to induce the immune system’s own response against cancer and infectious disease; TNFRSF25, which targets the T cell co-stimulator TNFRSF25 to regulate inflammation and immunosuppression, and RapidVax designed to induce immunological memory against emerging biological threats and accelerate timeline to the clinic.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)